8% royalty on global net sales on PD-991 is likely enough to move the needle - I could easily see upward of $1/share in EPS a few years out just from the royalty on this, given it's one of the most exciting new oncology prospects out there.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.